Advertisement

Topics

Phase 1/2 data show Roche's entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents http://bit.ly/2EiokZ4  #cancer #pharmapic.twitter.com/E46ihTUhgt

07:43 EDT 17 May 2019 | Pharmafile

Phase 1/2 data show Roche's entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents http://bit.ly/2EiokZ4 

Original Article: Phase 1/2 data show Roche's entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents http://bit.ly/2EiokZ4  #cancer #pharmapic.twitter.com/E46ihTUhgt

NEXT ARTICLE

More From BioPortfolio on "Phase 1/2 data show Roche's entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents http://bit.ly/2EiokZ4  #cancer #pharmapic.twitter.com/E46ihTUhgt"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...